KANJINTI vs TOLAK

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated October 9, 2026·How we rate

Possible drug interaction. KANJINTI and TOLAK are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	KANJINTI	TOLAK
Rating	72/100	74/100
Pharmacy pays	—	$0.61 /mL
Type	RX	RX
Active ingredient	TRASTUZUMAB-ANNS	FLUOROURACIL
Manufacturer	Amgen Inc	Hill Dermaceuticals
Dosage forms	Injectable	Topical
Drug class	—	Nucleoside Metabolic Inhibitor
Boxed warning	Boxed warning	None
Treats	Breast Neoplasms, Gastrointestinal Neoplasms	Breast Neoplasms, Basal Cell Carcinoma, Colonic Neoplasms

kanjinti tolak

Rating

72/100

74/100

Pharmacy pays

—

$0.61 /mL

Type

Active ingredient

TRASTUZUMAB-ANNS

FLUOROURACIL

Manufacturer

Amgen Inc

Hill Dermaceuticals

Dosage forms

Injectable

Topical

Drug class

—

Nucleoside Metabolic Inhibitor

Boxed warning

None

Treats

Breast Neoplasms, Gastrointestinal Neoplasms

Breast Neoplasms, Basal Cell Carcinoma, Colonic Neoplasms

Frequently asked questions

Which is better-rated, Kanjinti or Tolak?

By our independent rating, Tolak scores higher — 3.7 vs 3.6 out of 5 for Kanjinti. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Kanjinti and Tolak?

Kanjinti contains Trastuzumab-Anns, while Tolak contains Fluorouracil — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.